Aurora Spine (ASG) Stock Overview
Through its subsidiary, Aurora Spine, Inc., engages in the development and distribution of minimally invasive interspinous fusion systems and devices in Canada. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
ASG Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Aurora Spine Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.34 |
| 52 Week High | CA$0.49 |
| 52 Week Low | CA$0.23 |
| Beta | -0.011 |
| 1 Month Change | 11.48% |
| 3 Month Change | 7.94% |
| 1 Year Change | 21.43% |
| 3 Year Change | -32.00% |
| 5 Year Change | 17.24% |
| Change since IPO | -74.81% |
Recent News & Updates
Recent updates
Aurora Spine (CVE:ASG) Is Making Moderate Use Of Debt
May 07
Slammed 30% Aurora Spine Corporation (CVE:ASG) Screens Well Here But There Might Be A Catch
Feb 21Aurora Spine Corporation (CVE:ASG) Soars 26% But It's A Story Of Risk Vs Reward
Oct 19We Think Aurora Spine (CVE:ASG) Has A Fair Chunk Of Debt
Oct 16Aurora Spine Corporation's (CVE:ASG) Subdued P/S Might Signal An Opportunity
Aug 14We Think Shareholders May Want To Consider A Review Of Aurora Spine Corporation's (CVE:ASG) CEO Compensation Package
Jun 19Is Aurora Spine (CVE:ASG) A Risky Investment?
May 29There Is A Reason Aurora Spine Corporation's (CVE:ASG) Price Is Undemanding
Mar 19Would Aurora Spine (CVE:ASG) Be Better Off With Less Debt?
Oct 15Why Investors Shouldn't Be Surprised By Aurora Spine Corporation's (CVE:ASG) Low P/S
Aug 11Here's Why Aurora Spine (CVE:ASG) Can Afford Some Debt
May 01Aurora Spine (CVE:ASG) Is Making Moderate Use Of Debt
Dec 22Would Aurora Spine (CVE:ASG) Be Better Off With Less Debt?
Aug 23Health Check: How Prudently Does Aurora Spine (CVE:ASG) Use Debt?
May 04Health Check: How Prudently Does Aurora Spine (CVE:ASG) Use Debt?
Dec 23Aurora Spine (CVE:ASG) Is Making Moderate Use Of Debt
Jun 11A Look At The Intrinsic Value Of Aurora Spine Corporation (CVE:ASG)
Feb 26Is Aurora Spine (CVE:ASG) A Risky Investment?
Nov 19
Shareholder Returns
| ASG | CA Medical Equipment | CA Market | |
|---|---|---|---|
| 7D | 4.6% | -4.2% | 0.02% |
| 1Y | 21.4% | -36.5% | 16.6% |
Return vs Industry: ASG exceeded the Canadian Medical Equipment industry which returned -36.5% over the past year.
Return vs Market: ASG exceeded the Canadian Market which returned 17.8% over the past year.
Price Volatility
| ASG volatility | |
|---|---|
| ASG Average Weekly Movement | 9.4% |
| Medical Equipment Industry Average Movement | 10.8% |
| Market Average Movement | 8.7% |
| 10% most volatile stocks in CA Market | 18.3% |
| 10% least volatile stocks in CA Market | 3.1% |
Stable Share Price: ASG has not had significant price volatility in the past 3 months compared to the Canadian market.
Volatility Over Time: ASG's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | n/a | Trent Northcutt | www.aurora-spine.com |
Aurora Spine Corporation, through its subsidiary, Aurora Spine, Inc., engages in the development and distribution of minimally invasive interspinous fusion systems and devices in Canada. The company offers interspinous process lumbar fusion devices, such as the ZIP, ZIP ULTR, ZIP LP, and ZIP-51 for patients suffering from degenerative disc diseases. It also provides SOLO, an anterior lumbar interbody fusion 3D printed stand-alone lumbar fusion device, which is an integrated plate and spacer system that helps to preserve the natural anatomic profile while providing spinal column support and stability; and SiLo, a posterior allograft implant; and SiLO TFX, a titanium implant device for sacroiliac joint fusion.
Aurora Spine Corporation Fundamentals Summary
| ASG fundamental statistics | |
|---|---|
| Market cap | CA$26.54m |
| Earnings (TTM) | -CA$1.49m |
| Revenue (TTM) | CA$24.59m |
Is ASG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ASG income statement (TTM) | |
|---|---|
| Revenue | US$17.97m |
| Cost of Revenue | US$7.25m |
| Gross Profit | US$10.71m |
| Other Expenses | US$11.80m |
| Earnings | -US$1.09m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.014 |
| Gross Margin | 59.63% |
| Net Profit Margin | -6.04% |
| Debt/Equity Ratio | 66.4% |
How did ASG perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/07/21 16:12 |
| End of Day Share Price | 2025/07/21 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Aurora Spine Corporation is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Neal Gilmer | Clarus Securities Inc. |